Universität zu Köln

Stone, Gregory G., Seifert, Harald and Nord, Carl Erik (2020). In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015-2017. Int. J. Antimicrob. Agents, 56 (3). AMSTERDAM: ELSEVIER. ISSN 1872-7913

Full text not available from this repository.

Abstract

Background: Between 2015-2017, 21 850 Enterobacterales isolates and 6156 Pseudomonas aeruginosa (P. aeruginosa) isolates were collected by 77 centers in 18 European countries as part of the International Network for Optimal Resistance Monitoring (INFORM) study (which was included into the Antimicrobial Testing Leadership and Surveillance [ATLAS] study in 2018). Methods: A central reference laboratory performed antimicrobial susceptibility testing using broth microdilution panels according to Clinical and Laboratory Standards Institute guidelines. The presence of beta-lactamases was confirmed using multiplex PCR assays. Results: Among Enterobacterales isolates, the highest rates of susceptibility were to ceftazidimeavibactam (99.0%; MIC90 0.5 mg/L), meropenem (96.3%), amikacin (95.2%), and imipenem (92.8%). All Enterobacterales organisms were highly susceptible to colistin (>= 94.6%), apart from Proteus mirabilis, which is intrinsically resistant to colistin. Susceptibility rates among ceftazidime-resistant isolates were 95.7% for ceftazidime-avibactam and 87.9% for colistin, and 78.5% and 71.1%, respectively, among carbapenemasepositive isolates. Colistin was the only agent with activity against metallo-beta-lactamases (100% susceptibility) among Enterobacterales and P. aeruginosa isolates. Overall susceptibility rates among P. aeruginosa were highest to colistin (99.5%) and ceftazidime-avibactam (92.3%), and were similar to ceftazidimeresistant isolates for colistin (98.9%) and reduced to 66.2% for ceftazidime-avibactam. Susceptibility rates among multidrug-resistant P. aeruginosa isolates were 98.9% to colistin and 71.7% to ceftazidimeavibactam. Conclusions: Clinical isolates of Enterobacterales and P. aeruginosa collected from Europe, between 20152017, were highly susceptible to ceftazidime-avibactam, suggesting it is a useful alternative agent for patients whose treatment options may be limited. Persistent antimicrobial resistance requires continued surveillance and monitoring. (c) 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Stone, Gregory G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Seifert, Harald UNSPECIFIED UNSPECIFIED UNSPECIFIED Nord, Carl Erik UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-321628
DOI:	10.1016/j.ijantimicag.2020.106045
Journal or Publication Title:	Int. J. Antimicrob. Agents
Volume:	56
Number:	3
Date:	2020
Publisher:	ELSEVIER
Place of Publication:	AMSTERDAM
ISSN:	1872-7913
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PSEUDOMONAS-AERUGINOSA; RESISTANT ENTEROBACTERIACEAE; INTRAABDOMINAL INFECTIONS; GLOBAL SURVEILLANCE; SUSCEPTIBILITY; PROGRAM Multiple languages Infectious Diseases; Microbiology; Pharmacology & Pharmacy Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/32162